PRECIGEN, INC. Financial and Nonfinancial Liabilities, Fair Value Disclosure
PRECIGEN, INC. (PGEN) had Financial and Nonfinancial Liabilities, Fair Value Disclosure of $0 as of 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Net Asset (Liability)
us-gaap:LiabilitiesFairValueDisclosure · last filed 2026-03-25
- 2025-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $0.00.
- 2025-06-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $78.56M.
- 2025-03-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $83.02M.
- 2024-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $50.54M.
| Period end | Financial and Nonfinancial Liabilities, Fair Value Disclosure |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-25 |
| 2025-06-30 | $78.56M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $83.02M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $50.54M 10-K · filed 2026-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |